Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 44.3% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-0.9%)
  • Dividend yield for the last twelve months 4.0%
  • Free cash flow yield 6.6% (LTM)
  • Share price is 56.3% higher than minimum and 15.8% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (20.4x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+4.1%)61.99
year average price 50.20  


year start price 56.85 2025-02-08

max close price 63.11 2025-03-10

min close price 42.60 2025-10-29

current price 61.99 2026-02-07
Common stocks: 2 111 517 922

Dividend Yield:  4.0%
FCF Yield LTM: 6.6%
EV / LTM EBITDA: 20.4x
EV / EBITDA annualized: 13.2x
Last revenue growth (y/y):  +2.8%
Last growth of EBITDA (y/y):  +85.8%
Historical revenue growth:  +1.0%
Historical growth of EBITDA:  -2.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 130 893
Net Debt ($m): 33 300
EV (Enterprise Value): 164 193
EBITDA LTM ($m): 8 033
EV / LTM EBITDA: 20.4x
Price to Book: 7.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-06seekingalpha.com

Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026

2026-02-05youtube.com

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

2026-02-05seekingalpha.com

Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript

2026-02-05zacks.com

Weekly Jobless Claims Exceed Expectations

2026-02-05zacks.com

Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates

2026-02-05zacks.com

Jobless Claims Pop Up a Bit, Major Morning for Earnings

2026-02-05wsj.com

Bristol Myers Squibb Revenue Ticks Up on Immuno-Oncology Growth

2026-02-05reuters.com

Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off

2026-02-03zacks.com

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

2026-02-02zacks.com

Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data